The Stanford-Johns Hopkins Research Hub intends to gain a deeper understanding of molecular pathways to enhance the efficiency of nuclear reprogramming, to ensure the function and safety of induced pluripotential cells (IPSCs), to provide robust protocols for differentiation and purification of hematopoietic and endothelial lineages, and to guide pioneering work in pre-clinical studies of safety and efficacy. The Stanford group proposes three research projects. Project 1: Novel Regulators to enhance IPSC Derivation and Differentiation to EC (Helen Blau, Wing Wong). Using a novel cell fusion approach, we will identify the early epigenetic and transcriptional changes occurring during nuclear reprogramming of the human fibroblast nucleus after cell fusion with mouse ESC. Species-specific transcriptome amplification of the human RNA within the heterokaryon transcripts permits identification of the earliest transcriptional events in the human nucleus during reprogramming. Using the same cell fusion strategy, we will also elucidate the earliest events of directed differentiation toward endothelial cells. In Project 2: IPSC Engineering and Characterization (Renee Reijo Pera, James Swartz) we will develop and refine a protein-based strategy for generating iPSCs. We will synthesize cell-permeant fusion proteins comprising the Yamanaka factors with transduction domains, and optimize their dose, duration and timing to induce optimal reprogramming. Novel factors identified in Project 1 will be incorporated to enhance reprogramming. Comprehensive characterization of the safety and efficacy of these cells will include spectral karyotyping, mitochondrial gene expression and function, and epigenetic, transcriptional and tumorigenic profiling. In Project 3: iPSC-ECs for Therapeutic Angiogenesis: Determinants of Differentiation and Function (John Cooke), we will utilize the IPSC generated in Project 2, and the insights from Project 1 (and our Hopkins colleagues), to efficiently direct differentiation of the IPSC to endothelial lineage. EC function will be assessed in vitro and in vivo, and their therapeutic efficacy studied using molecular imaging and laser Doppler perfusion in a murine model of peripheral arterial disease. We intend that the insights from these projects ultimately lead to novel vascular therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01HL100397-05
Application #
8471163
Study Section
Special Emphasis Panel (ZHL1-CSR-J (S1))
Program Officer
Tolunay, Eser
Project Start
2009-09-30
Project End
2016-04-30
Budget Start
2013-08-08
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$797,222
Indirect Cost
$90,573
Name
Methodist Hospital Research Institute
Department
Type
DUNS #
185641052
City
Houston
State
TX
Country
United States
Zip Code
77030
Sukhovershin, Roman A; Cooke, John P (2016) How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs 16:153-61
Wong, Wing Tak; Cooke, John P (2016) Therapeutic transdifferentiation of human fibroblasts into endothelial cells using forced expression of lineage-specific transcription factors. J Tissue Eng 7:2041731416628329
Giordano, Samantha; Zhao, Xiangmin; Xing, Daisy et al. (2016) Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat. Am J Physiol Heart Circ Physiol 310:H705-15
Durruthy-Durruthy, Jens; Sebastiano, Vittorio; Wossidlo, Mark et al. (2016) The primate-specific noncoding RNA HPAT5 regulates pluripotency during human preimplantation development and nuclear reprogramming. Nat Genet 48:44-52
Zhou, Gang; Meng, Shu; Li, Yanhui et al. (2016) Optimal ROS Signaling Is Critical for Nuclear Reprogramming. Cell Rep 15:919-25
Molinaro, Roberto; Boada, Christian; Del Rosal, Guillermo Medrano et al. (2016) Vascular Inflammation: A Novel Access Route for Nanomedicine. Methodist Debakey Cardiovasc J 12:169-174
Meng, Shu; Zhou, Gang; Gu, Qilin et al. (2016) Transdifferentiation Requires iNOS Activation: Role of RING1A S-Nitrosylation. Circ Res 119:e129-e138
Cui, Jun; Rothstein, Megan; Bennett, Theo et al. (2016) Quantification of dopaminergic neuron differentiation and neurotoxicity via a genetic reporter. Sci Rep 6:25181
Bassous, Nicole; Cooke, John P; Webster, Thomas J (2016) Enhancing Stent Effectiveness with Nanofeatures. Methodist Debakey Cardiovasc J 12:163-168
Yepuri, Gautham; Sukhovershin, Roman; Nazari-Shafti, Timo Z et al. (2016) Proton Pump Inhibitors Accelerate Endothelial Senescence. Circ Res 118:e36-42

Showing the most recent 10 out of 138 publications